{
    "id": 80375,
    "name": "gastroesophageal adenocarcinoma",
    "source": "DOID",
    "definition": "A gastroesophageal cancer that has_material_basis_in abnormally proliferating cells, derives_from epithelial cells, which originate in glandular tissue. [url:https\\://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827797]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0080375",
    "evidence": [
        {
            "id": 16768,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, GBR 1302 treatment resulted in prolonged (more than 4 months) stable disease in a patient with ERBB2 (HER2) positive (IHC 3+) gastroesophageal adenocarcinoma (Annals of Oncology, Volume 29, Issue suppl_8, October 2018, mdy288.020; NCT02829372).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 8171,
                "therapyName": "GBR1302",
                "synonyms": null
            },
            "indication": {
                "id": 80375,
                "name": "gastroesophageal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14826,
                    "pubMedId": null,
                    "title": "GBR1302: a BEAT bispecific antibody for the treatment of HER2 positive cancers",
                    "url": "https://www.ejcancer.com/article/S0959-8049(14)70265-5/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17157,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, AMG 337 treatment resulted in an objective response rate of 18% (8/45, 8 partial responses) and stable disease in 36% (16/45) of patients with MET-amplified gastroesophageal adenocarcinoma (PMID: 30366938; NCT02016534).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 80375,
                "name": "gastroesophageal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15223,
                    "pubMedId": 30366938,
                    "title": "A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30366938"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 20572,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial that supported FDA approval, the Herceptin (trastuzumab) biosimilar Kanjinti (Trastuzumab-anns) demonstrated structure, function, and pharmacokinetic profile comparable to Herceptin (trastuzumab) (PMID: 28341959), thus supporting the extrapolation of data from the Phase III trial that supported the approval of Herceptin (trastuzumab) in Erbb2 (Her2) overexpressing gastrioesophageal adenocarcinoma (PMID: 20728210; NCT01041404) for approval of Kanjinti (Trastuzumab-anns) (FDA.gov).",
            "molecularProfile": {
                "id": 1270,
                "profileName": "ERBB2 over exp"
            },
            "therapy": {
                "id": 6243,
                "therapyName": "Trastuzumab-anns",
                "synonyms": null
            },
            "indication": {
                "id": 80375,
                "name": "gastroesophageal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 286,
                    "pubMedId": null,
                    "title": "FDA.gov",
                    "url": "http://www.fda.gov/"
                },
                {
                    "id": 893,
                    "pubMedId": 20728210,
                    "title": "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20728210"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 17932,
                    "pubMedId": null,
                    "title": "Kanjinti (Trastuzumab-anns) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761073"
                },
                {
                    "id": 17935,
                    "pubMedId": 28341959,
                    "title": "A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28341959"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02824042",
            "title": "Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 4594,
                    "therapyName": "Anetumab ravtansine + Itraconazole",
                    "synonyms": null
                },
                {
                    "id": 4593,
                    "therapyName": "Anetumab ravtansine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02954536",
            "title": "Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4945,
                    "therapyName": "Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03697304",
            "title": "Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 na\u00efve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours.",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5692,
                    "therapyName": "BI 754091",
                    "synonyms": null
                },
                {
                    "id": 5690,
                    "therapyName": "BI 754111",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03783936",
            "title": "Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8350,
                    "therapyName": "Avelumab + Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 8349,
                    "therapyName": "Avelumab + Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03821233",
            "title": "A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9492,
                    "therapyName": "ZW49",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03921021",
            "title": "Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9570,
                    "therapyName": "OBP-301 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03929666",
            "title": "A Safety and Efficacy Study of ZW25 Plus Combination Chemotherapy in HER2-expressing Gastroesophageal Adenocarcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8232,
                    "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + ZW25",
                    "synonyms": "mFOLFOX6 + ZW25"
                },
                {
                    "id": 8231,
                    "therapyName": "Cisplatin + Fluorouracil + Leucovorin + ZW25",
                    "synonyms": null
                },
                {
                    "id": 8230,
                    "therapyName": "Capecitabine + Cisplatin + ZW25",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04021108",
            "title": "Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1312,
                    "therapyName": "Nivolumab",
                    "synonyms": null
                },
                {
                    "id": 7184,
                    "therapyName": "Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin",
                    "synonyms": "Nivolumab + FOLFOX"
                }
            ]
        },
        {
            "nctId": "NCT04029922",
            "title": "Study of MT-5111 in HER2-positive Solid Tumors (MT-5111)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8209,
                    "therapyName": "MT-5111",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04060342",
            "title": "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8693,
                    "therapyName": "GB1275",
                    "synonyms": null
                },
                {
                    "id": 8694,
                    "therapyName": "GB1275 + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 8695,
                    "therapyName": "GB1275 + Gemcitabine + Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04150640",
            "title": "P2 5-FU, Oxaliplatin & Liposomal Irinotecan (Nal-IRI) in 1st Line Advanced Esophageal & Gastric",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8919,
                    "therapyName": "Fluorouracil + MM-398 + Oxaliplatin",
                    "synonyms": null
                },
                {
                    "id": 8920,
                    "therapyName": "Fluorouracil + MM-398 + Oxaliplatin + Trastuzumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04164979",
            "title": "Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5680,
                    "therapyName": "Cabozantinib + Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04198766",
            "title": "Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9075,
                    "therapyName": "INBRX-106",
                    "synonyms": null
                },
                {
                    "id": 9076,
                    "therapyName": "INBRX-106 + Pembrolizumab",
                    "synonyms": null
                }
            ]
        }
    ]
}